1. Ibrutinib-based therapy for the treatment of marginal zone lymphoma with central nervous system involvement.
- Author
-
Furqan, Fateeha, Watson, Grace, Samaniego, Felipe, Fayad, Luis E., Rashmi Kanagal-Shamanna, Morrison, Michael W., Thompson, Philip A., Steiner, Raphael E., Chi, Linda, Dabaja, Bouthaina, Pinnix, Chelsea C., Neelapu, Sattva S., Nastoupil, Loretta J., and Strati, Paolo
- Subjects
CENTRAL nervous system ,LYMPHOMAS ,MANTLE cell lymphoma ,B cell receptors ,INSTITUTIONAL review boards - Abstract
MZL rarely involves the central nervous system (CNS) and accounts for only 1.4% of all CNS lymphomas [[2]]. While activity has been shown for the treatment of CNS involvement of other indolent B-cell NHL, such as chronic lymphocytic leukemia (CLL) [[8]], its efficacy in CNS MZL has not been previously reported. Radiological and pathological findings in a patient with marginal zone lymphoma (MZL) and central nervous system (CNS) involvement (patient 5). In a recent multicenter study, patients with CNS MZL were treated with surgery, methotrexate-based chemotherapy and/or radiation [[12]], the latter in light of the radio-sensitivity typically reported for extra-nodal CNS MZL [[13]]. [Extracted from the article]
- Published
- 2020
- Full Text
- View/download PDF